Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); Protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults

BMJ Open

Volumn 5, Issue 10, 2015, Pages

  Green, C A ^a   Scarselli, E ^b   Voysey, M ^a,c   Capone, S ^b   Vitelli, A ^b   Nicosia, A ^b   Cortese, R ^b   Thompson, A J ^a   Sande, C S ^a   De Lara, Catherine ^d   Klenerman, P ^d   Pollard, A J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Formerly Okairos Srl ^*  (Italy)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RESPIRATORY SYNCYTIAL VIRUS PROTEIN F; RESPIRATORY SYNCYTIAL VIRUS PROTEIN M2 1; RESPIRATORY SYNCYTIAL VIRUS PROTEIN N; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRAL PROTEIN;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; LOW DRUG DOSE; MALE; METHODOLOGY; MODIFIED VACCINIA VIRUS ANKARA; NORMAL HUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PREGNANCY OUTCOME; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RISK ASSESSMENT; SIMIAN VIRUS; SINGLE DRUG DOSE; VACCINATION; VACCINIA VIRUS; VIRUS REPLICATION; ADOLESCENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GENE VECTOR; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; MIDDLE AGED; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; YOUNG ADULT;

ADENOVIRUSES, SIMIAN; ADOLESCENT; ADULT; AGED; CLINICAL PROTOCOLS; FEMALE; GENETIC VECTORS; HUMANS; MALE; MIDDLE AGED; RESEARCH DESIGN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; VACCINATION; VACCINIA VIRUS; VIRAL PROTEINS; YOUNG ADULT;

EID: 84949524619     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-008748     Document Type: Article

References (44)

1. Glezen WP, Taber LH, Frank AL, et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986;140:543-6.
2. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009;360:588-98.
3. Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child 2003;88:1065-9.
4. [No authors listed]. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998;102(3 Pt 1):531-7.
5. Boyce TG, Mellen BG, Mitchel EF Jr, et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 2000;137:865-70.
6. Paediatric Intensive Care Audit Network. http://www.picanet.org.uk/Audit/Annual-Reporting/PICANet-Annual-Report-2013-summary. pdf
7. Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 2011;162:80-99.
8. Szabo SM, Gooch KL, Bibby MM, et al. The risk of mortality among young children hospitalized for severe respiratory syncytial virus infection. Paediatr Respir Rev 2013;13(Suppl 2):S1-8.
9. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-128.
10. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-Analysis. Lancet 2010;375:1545-55.
11. Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013;368:1791-9.
12. Sigurs N, Aljassim F, Kjellman B, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 2010;65:1045-52.
13. Murray J, Bottle A, Sharland M, et al. Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study. PLoS ONE 2014;9:e89186.
14. O'Shea MK, Ryan MA, Hawksworth AW, et al. Symptomatic respiratory syncytial virus infection in previously healthy young adults living in a crowded military environment. Clin Infect Dis 2005;41:311-17.
15. Hall CB, Long CE, Schnabel KC. Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis 2001;33:792-6.
16. Renaud C, Xie H, Seo S, et al. Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant 2013;19:1220-6.
17. Lee N, Lui GC, Wong KT, et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis 2013;57:1069-77.
18. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179-86.
19. Parnes C, Guillermin J, Habersang R, et al. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. Pediatr Pulmonol 2003;35:484-9.
20. Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005;352:1749-59.
21. Fulginiti VA, Eller JJ, Sieber OF, et al. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969;89:435-48.
22. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969;89:422-34.
23. Kapikian AZ, Mitchell RH, Chanock RM, et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969;89:405-21.
24. Chin J, Magoffin RL, Shearer LA, et al. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 1969;89:449-63.
25. Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine 1996;14:1214-18.
26. Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine 1997;15:1130-2.
27. Openshaw PJ, Clarke SL, Record FM. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol 1992;4:493-500.
28. Glenn GM, Smith G, Fries L, et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 2013;31:524-32.
29. Bernstein DI, Malkin E, Abughali N, et al. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J 2012;31:109-14.
30. Yang CF, Wang CK, Malkin E, et al. Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine. Vaccine 2013;31:2822-7.
31. Malkin E, Yogev R, Abughali N, et al. Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age. PLoS ONE 2013;8:e77104.
32. Karron RA, Wright PF, Belshe RB, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005;191:1093-104.
33. Gilbert SC. Clinical development of Modified Vaccinia virus Ankara vaccines. Vaccine 2013;31:4241-6.
34. Rollier CS, Reyes-Sandoval A, Cottingham MG, et al. Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol 2011;23:377-82.
35. Capone S, D'Alise AM, Ammendola V, et al. Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Rev Vaccines 2013;12:379-93.
36. Swadling L, Capone S, Antrobus RD, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med 2014;6:261ra153.
37. Taylor G, Thom M, Capone S, et al. Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections. Sci. Transl. Med. 7, 300ra127 (2015).
38. Colloca S, Barnes E, Folgori A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012;4:115ra2.
39. Pierantoni A, Esposito ML, Ammendola V, et al. Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates. Mol Ther Methods Clin Dev 2015;2:15018.
40. Vitelli A, Quirion MR, Lo CY, et al. Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus. PLoS ONE 2013;8: e55435.
41. Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010;63:834-40.
42. Damocles Study Group, NHS Health Technology Assessment Programme. A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet 2005;365:711-22.
43. Waris ME, Tsou C, Erdman DD, et al. Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV. J Virol 1997;71:6935-9.
44. Olson MR, Varga SM. CD8T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. J Immunol 2007;179:5415-24.